Giant Biogene Holding Co., Ltd. (HKG:2367)

Market Cap	31.91B -62.6%
Revenue (ttm)	6.14B -0.4%
Net Income	2.13B -7.2%
EPS	2.01 -12.1%
Shares Out	1.06B
PE Ratio	14.92
Forward PE	14.42
Dividend	1.40 (4.66%)
Ex-Dividend Date	Jun 1, 2026

Volume	7,555,461
Open	28.50
Previous Close	30.06
Day's Range	27.90 - 29.56
52-Week Range	26.40 - 71.00
Beta	0.72
Analysts	Strong Buy
Price Target	44.09 (+49.56%)
Earnings Date	Jun 3, 2026

About Giant Biogene Holding

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded ...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 2,201
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2367

Financial Performance

In 2025, Giant Biogene Holding's revenue was 5.52 billion, a decrease of -0.37% compared to the previous year's 5.54 billion. Earnings were 1.91 billion, a decrease of -7.15%.

Financial numbers in CNY